Myriad Genetics, Inc.
Myriad Genetics, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Salt Lake City, UT. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $825 million and a loss of $366 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2835, In Vitro & In Vivo Diagnostic Substances); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 6.5 out of ten, present 5.7 out of ten, future 5.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.5 out of ten. 1 warning event since 2017; the latest 2021-03-02. 75th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.2 out of ten. +1.5% a year over 10 filed years; profitable in 3 of 10. 52nd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.5 out of ten. CrossAssetData estimate 7.5/10, confidence 35 of 100 (one part). 75th percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
- Financial health (present): 6.0 out of ten. ROE -99%: lost 99¢ per shareholder dollar. Leverage 48%: owes 48¢ per asset dollar. 60th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 6.1 out of ten. top 39% of 17 in its family; net margin -44.4%. 61st percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 4.4 out of ten. bottom 44% of 15 in its family for leadership; chief executive since 2025. 44th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 6.3 out of ten. top 37% of 16 in its family for room to expand. 63rd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 7.4 out of ten. top 26% of 17 in its family for growth drivers. 74th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 2.5 out of ten. bottom 25% of 16 in its family for expectations against reality. 25th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-31 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 1996. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Hereditary Cancer 45%, Prenatal 23%, Mental Health 18%, Tumor Profiling 15%. By geography: United States 93%, Outside the United States 7%. As tagged in its annual report (Form 10-K, filed 2026-02-24).
Who runs it
Raha, Samraat S. (President and CEO); Wheeler, Benjamin Richard (Chief Financial Officer); Leffler, Scott J. (Chief Financial Officer); Verratti, Mark (Chief Operating Officer); Donnelly, Brian J (Chief Commercial Officer); Fox, Jennifer Lynne (Chief Legal Officer); Jampa, Raj (Chief Technology Officer); Muzzey, Dale (Chief Scientific Officer); Haas, Kevin Richard (Chief Technology Officer); Solaiman, Shereen (Chief People Officer); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.